Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt, A. Götz, Matthias H. Tschöp, et al.
Peptides (2018) Vol. 100, pp. 190-201
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang, Qingtong Zhou, Viktorija Labroska, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 425
Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies
Miguel A. Sánchez-Garrido, Manuel Tena‐Sempere
Molecular Metabolism (2020) Vol. 35, pp. 100937-100937
Open Access | Times Cited: 376
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
Timo D. Müller, Christoffer Clemmensen, Brian Finan, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 4, pp. 712-746
Open Access | Times Cited: 163
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Fenghui Zhao, Qingtong Zhou, Zhaotong Cong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 94
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits
Anke Hinney, Antje Körner, Pamela Fischer‐Posovszky
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 10, pp. 623-637
Open Access | Times Cited: 77
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
Nicholas K. Smith, Troy A. Hackett, Aurelio Galli, et al.
Neurochemistry International (2019) Vol. 128, pp. 94-105
Open Access | Times Cited: 113
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Role of pyroptosis in liver diseases
Abdullah Al Mamun, Yanqing Wu, Chang Jia, et al.
International Immunopharmacology (2020) Vol. 84, pp. 106489-106489
Closed Access | Times Cited: 75
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen, Mikkel Christensen
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 3, pp. 231-243
Closed Access | Times Cited: 70
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism
Jia Duan, Xinheng He, Shujie Li, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 12
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Anna M. Puszkarska, Bruck Taddese, Jefferson D. Revell, et al.
Nature Chemistry (2024) Vol. 16, Iss. 9, pp. 1436-1444
Open Access | Times Cited: 11
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Marta Seghieri, Alexander S. Christensen, Andreas Andersen, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 78
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kook Hwan Kim, Myung‐Shik Lee
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 67
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Patrick Gilon
Journal of Molecular Biology (2020) Vol. 432, Iss. 5, pp. 1367-1394
Closed Access | Times Cited: 64
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
David S. Mathiesen, Jonatan I. Bagger, Natasha C. Bergmann, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4092-4092
Open Access | Times Cited: 62
Anti-diabetic effects of bioactive peptides: recent advances and clinical implications
Caleb Acquah, Christian K. O. Dzuvor, Susan M. Tosh, et al.
Critical Reviews in Food Science and Nutrition (2020) Vol. 62, Iss. 8, pp. 2158-2171
Closed Access | Times Cited: 61
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
Gianluca Svegliati‐Baroni, Bárbara G. Patrício, Gessica Lioci, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5820-5820
Open Access | Times Cited: 53
Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application
Mona C. Löffler, Matthias J. Betz, Denis P. Blondin, et al.
Molecular Metabolism (2021) Vol. 51, pp. 101237-101237
Open Access | Times Cited: 53
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty, Finbarr O’Harte, Nigel Irwin, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 49
Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update
Nhung Thi Phuong Nong, Jue‐Liang Hsu
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9508-9508
Open Access | Times Cited: 43
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
Jan Pawlas, Timo Nuijens, Jonas Persson, et al.
Green Chemistry (2019) Vol. 21, Iss. 23, pp. 6451-6467
Closed Access | Times Cited: 52
GIP analogues and the treatment of obesity-diabetes
Clifford J. Bailey
Peptides (2019) Vol. 125, pp. 170202-170202
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top